Company intelligence / Profile preview

Sobel

Vancouver, Canada

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Vinia® (red grape-derived compound with piceid resveratrol) demonstrates clinical efficacy in increasing arterial dilation, blood flow, oxygen delivery, and brain function. Over 50,000 active subscribers with 4.8-star average rating from 9,000 verified reviews; generated over $50 million in direct-to-consumer (D2C) revenues since May 2021 US launch.

Therapeutic areas: CardiovascularNeurologyGastroenterologyMetabolic Disorders
Modalities: Plant cell-derived bioactive compounds (botanical synthesis)
Industry: Non-Drug Biotech

Partnerships

Tate & Lyle (sweet protein development)Contract Development and Manufacturing Organization (CDMO) serving pharmaceutical, cosmetic, and nutrition customers

Beyond the preview

Go deeper on Sobel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sobel.

Explore the full profile